36C25520Q0275-001.pdf

VA Heartland Network- VISN 15

STATEMENT OF REQUIREMENT

Blood Bank Liquid Reagents

DESCRIPTION/SPECIFICATIONS/STATEMENT OF REQUIREMENTS

SCOPE OF PROCUREMENT:

• It is the intent of the Department of Veterans Affairs, (herein afterwards referred to as VISN 15) to establish an agreement for immunohematology reagents for transfusion medicine testing.

• The Government will award a BPA to multiple Contractors for immunohematology reagents.

Contractor agrees to the following terms of the BPA exclusively with the VISN facilities in Attachment A and awarded in the final BPA.

• However, as requirements change, facilities within VISN 15 may be added or deleted by supplemental agreement of the Government and the Contractor. Additional reagents may be added to the BPA as new technology becomes available on the market and added to the base FSS contract

• VISN 15 will provide an estimated volume by reagent as reflected in Attachment A for each individual medical center and outpatient clinic laboratory. The Government estimates the volumes per facility as listed in Attachment A but does not guarantee volumes as listed; they are estimates ONLY.

• This will be a multiple vendor award with one base year and four, one-year options. VISN 15 intends to establish the base year of the agreement starting on 06/01/2020, with contract completion 05/31/2025. This agreement shall not exceed five years from date of award.

• The participating facilities may order products via Electronic Data Interchange (EDI), telephone, facsimile or other written communication, identifying the products by number, quantity, purchase price, address for delivery, and any special instructions.

• The delivery terms for all items ordered under the BPA will be FOB Origin. Contractor will make shipping arrangements and prepay all shipping and handling costs. Contractor will promptly replace all Products lost or damaged in shipment. Contractor will be responsible for all disputes with the shipper and all insurance claims related to the shipment.

• Contractor will accept return of erroneously shipped Products, in accordance with the following:

Contractor will credit Customer 100% of the Purchase Price for Products returned due to shipping errors, provided that Customer requests a Return Material Authorization (RMA) number from the Contractor in its notice to Contractor of a shipping error, and that Customer returns the Products within (30) days after its receipt of a RMA number. Returns will have RMA number written clearly on the outside of the shipping container. Contractor will not accept returns of Products ordered in error by Customer.

GENERAL REQUIREMENTS

• The desired reagents shall have the capability of performing as defined in the statement of work.

• The reagent shall be acquired for each of the clinical laboratories located at the VISN facilities listed in

Attachment A.

• The Contractor is required to provide a continuously stocked inventory of reagents, controls, and supplies required to ensure that patient care operations are not interrupted. These items shall be of the highest quality, sensitivity, specificity and tested to assure precision and accuracy. Expiration date must be clearly marked on reagent, standards and control containers. Alert/Notification of any delays in shipment as well as any or all technical advisory/recalls/alerts, prior to or simultaneously with field alerts should be forwarded to the designated individuals determined at contract award.

• Special handling for emergency orders of supplies: In the event that the supplies are found to be defective and unsuitable for use with the Contractor’s equipment, or the Contractor has failed to comply with the requirements for routine supply delivery, the Contractor is required to deliver the supplies within 24 hours of receipt of a verbal order for emergency delivery. If either circumstance has occurred, the Contractor shall deliver to the Government site in the most expeditious manner possible without additional cost to the Government, the necessary consumables in sufficient quantity as required to allow operation of the Contractor’s equipment for one week (under normal Government test load volume). If additional requests for emergency supply delivery are required by the Government, they shall be honored by the Contractor until the arrival at the laboratory of the monthly standing order/routine supplies delivery.

REAGENT MENU: Refer to Attachment A for desired reagent menu and estimated annual volumes. This solicitation uses a Brand Name or Equal Description of the product required. This permits prospective contractors to offer products other than those specifically referenced by brand name.

GENERAL FEATURES:

Technical Features:

• The following products should be available o Reagent Red Blood Cells o Blood Grouping Reagents o Anti-Human Globulin o Products for antibody investigation

• Products should work for a variety of testing formats, including, slide and tube testing.

• Products should be an FDA licensed product.

• Vendor should provide antigrams listing the antigen typing of cell in the screens and panels.

• Vendor should provide standing orders and on-demand shipping products.

• Red cell suspensions must be 2-4% (unless otherwise specified) to allow for use with tube testing.

• Complement Control Cells must be a 2-4% suspension of red cells coated with C3b (C3b/C3d) to be used as a quality control product when performing complement testing on patient red cells.

• Coombs Control cells must be a 4-6% suspension of group O red cells sensitized with an IgG antibody to be used as a quality control product when performing Coombs crossmatches.

• CorQC kit must provide an antiserum containing a blend of polyclonal and monoclonal antibodies and a Group AB+ red blood cell suspension (2-4%) to be used as a quality control product for red blood cell.

• Reference cells must be a 2-4% suspension of pooled C-D-E- red cells to use in ABO Serum Grouping.

• Panoscreen reagents must be tested by two independent lab using sources of antibody (except where precluded by the rarity of the antibody) to confirm the presence or absence of all blood group antigens specified on the Master List. Product should have a negative direct antiglobulin test using polyspecific Anti-human Globulin.

• Panocell reagents must be a 2-4% suspension of group O red blood cells. Reagents must be tested by two independent lab using sources of antibody (except where precluded by the rarity of the antibody) to confirm the presence or absence of all blood group antigens specified on the Master List.

• A1 and B cells must be a 2-4% suspension of C-, E-, D- red cells capable of detecting all major subgroups of Group A and Group B patients.

PARTICIPATING MEDICAL CENTERS:

Participating Medical Centers: The following medical centers shall be authorized to place delivery orders against the BPA.

• VA Medical Center, 800 Hospital Drive, Columbia, Missouri 65201-5275 VA

• Medical Center, 4801 Linwood Blvd, Kansas City, Missouri 64128-2226 VA

• Medical Center, 4101 S. 4th Street, Leavenworth, Kansas 66048-5014 VA

• Medical Center, 2401 West Main St., Marion, Illinois 62959-1188

• VA Medical Center, 1500 N. Westwood Blvd., Poplar Bluff, Missouri 63901-

• VA Medical Center, 915 N. Grand, St. Louis, MO 63108

• VA Medical Center, 2200 Gage Blvd., Topeka, Kansas 66622-0001

• VA Medical Center, 5500 East Kellogg, Wichita, Kansas 67218-1607